Seismic Pharmaceuticals begins 600-patient global Phase III study of istaroxime

Seismic Pharmaceuticals has enrolled the first patient in RESCUE HF-CS, a global Phase III clinical trial evaluating istaroxime in patients with cardiogenic shock caused by acute heart failure. The study is expected to enroll approximately 600 patients across the United States, Europe, China and South America, building on several completed Phase II programmes in which more than 350 patients were enrolled. Seismic is seeking to develop istaroxime as the first drug specifically approved for cardiogenic shock, a life-threatening syndrome for which no medication is currently approved by the United States Food and Drug Administration.

Istaroxime is an intravenous calcitrope with two pharmacological mechanisms: inhibition of the sodium-potassium ATPase and activation of SERCA2a. Seismic believes that combination can improve systolic contraction while also supporting diastolic relaxation, potentially differentiating the drug from conventional inotropes used off-label in critically ill patients. Phase II work has shown effects on blood pressure and cardiac function, but Phase III has to determine whether those physiological effects translate into clinically meaningful benefit across a much larger and more heterogeneous population.

Why is cardiogenic shock a difficult condition for a conventional randomized drug trial?

Cardiogenic shock develops when the heart cannot pump enough blood to maintain adequate circulation to vital organs. Patients can deteriorate rapidly, creating a setting in which treatment decisions occur under severe time pressure and where underlying causes, organ failure and supportive interventions vary considerably between individuals.

That heterogeneity makes drug development difficult. A therapy may improve blood pressure without necessarily improving survival or reducing the need for mechanical circulatory support, while outcomes can be influenced by the severity of shock before treatment begins.

The RESCUE HF-CS programme is focused on cardiogenic shock related to acute heart failure, which narrows the population compared with including every cause of shock. ClinicalTrials.gov describes the programme as a randomized, double-blind Phase IIb/III study comparing istaroxime plus standard care with placebo plus standard care. Participants receive a 48-hour intravenous infusion and are followed through 30 and 90 days.

The study therefore has to evaluate much more than whether istaroxime temporarily increases a hemodynamic number. Clinical outcomes including worsening heart failure, invasive interventions, mortality-related events, symptoms and quality of life are part of the broader development question.

What makes istaroxime mechanistically different from drugs already used in cardiogenic shock?

Conventional inotropic medicines can increase the strength of cardiac contraction, but some do so at the cost of higher heart rate, arrhythmias or increased myocardial oxygen demand. Those trade-offs can be particularly problematic in a heart already failing under severe physiological stress.

Istaroxime is designed to improve contractility through sodium-potassium ATPase inhibition while activating SERCA2a, a calcium-handling protein involved in cardiac relaxation. Seismic argues that this dual action can support both contraction and diastolic function rather than forcing clinicians to trade one against the other.

In Phase II studies, Seismic says istaroxime reduced heart rate and, in a subset of continuously monitored patients, reduced measures associated with ventricular arrhythmias. These findings are encouraging but remain part of the previous clinical evidence rather than proof of Phase III success.

The pivotal question is whether the mechanism remains beneficial when tested across hundreds of patients, multiple regions and ordinary clinical practice. Many cardiovascular drugs have produced attractive hemodynamic effects without ultimately improving the outcomes that matter most to patients.

Why is Seismic Pharmaceuticals moving so quickly after being formed only in 2026?

Seismic Pharmaceuticals was created in March 2026 around a portfolio acquired from Windtree Therapeutics, with financing led by Panacea Capital. Istaroxime arrived at Seismic as a Phase III-ready asset rather than as a newly discovered molecule needing years of preclinical and early-stage testing.

That acquisition model explains the rapid timeline. Seismic’s value proposition is partly based on unlocking an already developed cardiovascular asset whose previous owner had generated substantial clinical data.

The company also inherited a broader follow-on portfolio. Seismic 101, Seismic 102 and Seismic 103 are preclinical programmes targeting different aspects of acute heart failure, diastolic dysfunction and pulmonary hypertension, with clinical entry expected beginning in 2027.

That gives Seismic a pipeline beyond istaroxime, but the company remains highly dependent on its lead programme. A successful pivotal study could validate both the asset acquisition strategy and Seismic’s cardiovascular development organization. Failure would remove the most advanced programme and leave the company relying on much earlier-stage candidates.

How large is the regulatory opportunity if istaroxime succeeds?

The regulatory opportunity is notable because Seismic says there is no FDA-approved medication specifically for cardiogenic shock. Clinicians currently rely on supportive care, vasoactive drugs, inotropes, mechanical devices and treatment of the underlying cardiac problem rather than a medicine approved specifically for this syndrome.

A first approved drug could therefore enter a treatment environment without a direct regulatory predecessor. That does not mean commercial adoption would be automatic. Critical-care physicians would still compare clinical outcome data, safety, dosing complexity and cost with existing off-label treatment practices.

Hospital economics are also different from chronic outpatient markets. Cardiogenic shock is an acute event requiring intensive care, so the addressable population may be smaller than large chronic cardiovascular conditions even though treatment intensity and unmet need are high.

Commercial value would depend on how broadly the eventual label is written and whether benefit is demonstrated across different severity groups. A narrow indication in carefully selected patients would create a different market from broad use across heart-failure-related cardiogenic shock.

What evidence would make RESCUE HF-CS a genuine breakthrough rather than another positive cardiovascular trial?

The strongest result would be clinically meaningful improvement in outcomes rather than a statistically significant change in blood pressure alone. Reduced mortality, fewer invasive interventions or less worsening heart failure would be more persuasive to clinicians and payers than a narrow physiological endpoint.

Safety will be equally important. Any therapy used in unstable cardiac patients has to avoid adding meaningful arrhythmia or ischemic risk while providing hemodynamic benefit.

Consistency across regions can strengthen the regulatory case because the trial spans the United States, Europe, China and South America. A treatment effect that persists across healthcare systems and patient groups is more convincing than one concentrated in a small subgroup.

Seismic has advanced istaroxime to the stage at which its scientific premise faces the definitive test. Hundreds of patients have already generated Phase II experience. The next approximately 600 patients will determine whether that evidence can become an approvable cardiovascular therapy.

Key takeaways on Seismic Pharmaceuticals’ istaroxime Phase III trial

• Seismic Pharmaceuticals has enrolled the first patient in RESCUE HF-CS.
• Approximately 600 patients are expected to participate.
• Sites will span the United States, Europe, China and South America.
• Istaroxime is being developed for cardiogenic shock associated with acute heart failure.
• No medication is currently FDA-approved specifically for cardiogenic shock.
• Istaroxime combines sodium-potassium ATPase inhibition with SERCA2a activation.
• More than 350 patients have participated across prior Phase II programmes.
• The treatment is administered through a 48-hour intravenous infusion in the pivotal programme.
• Seismic Pharmaceuticals was formed in 2026 around assets acquired from Windtree Therapeutics.
• Clinical outcome benefit and safety, not only hemodynamic improvement, will determine the programme’s value.